Introduction
============

Hemophagocytic syndrome \[HPS; also known as hemophagocytic lymphohistiocytosis (HLH)\] is a disorder characterized by the benign proliferation of mature histiocytes and uncontrolled phagocytosis of the platelets, erythrocytes, lymphocytes, and their hematopoietic precursors in the bone marrow, giving rise to cytopenia. The disorder is classified into primary (familial) and secondary forms. Secondary HPS is usually caused by infectious diseases, autoimmune diseases, malignancies, or drugs. Among infectious diseases, viral infection is the most common cause of HPS, and tuberculosis-associated HPS is relatively rare. To our knowledge, only 10 cases of tuberculosis-associated HPS in subjects less than 20 years of age have been reported in the English literature. We herein present the case of a 19-year-old Japanese woman with miliary tuberculosis-associated HPS.

Case Report
===========

A 19-year-old Japanese woman was admitted to a local community hospital (day 1) with a 6-day history of a fever, chills, dyspnea, and general malaise. Chest computed tomography (CT) obtained at the hospital showed diffuse ground-glass opacity in both lungs and multiple mediastinal lymphadenopathy ([Fig. 1](#g001){ref-type="fig"}), and empiric antibiotic therapy (SBT/ABPC, MINO) was started. She underwent a transbronchial lung biopsy (TBLB) and bronchoalveolar lavage (BAL) on day 4 that disclosed noncaseating epithelioid granuloma without any organisms. Acid-fast staining of the sputum (three sets) and bronchoalveolar lavage fluid (BALF) also showed negative results. After a bronchoscopic examination, she developed respiratory failure, and steroid pulse therapy was started (day 4). After the steroid pulse therapy, her breathing state and pulmonary abnormal findings on computed tomography (CT) improved (day 9). However, on day 13, the high fever recurred during steroid reduction, and her multiple mediastinal lymphadenopathy persisted. In addition, her plasma soluble interleukin-2 receptor (sIL-2R) level was elevated (2,587 pg/mL). Therefore, the previous doctor suspected malignant lymphoma, and she was referred to our hospital for a definitive diagnosis.

![CT at the previous hospital showed diffuse ground-glass opacity in both lungs and multiple mediastinal lymphadenopathy.](1349-7235-56-1591-g001){#g001}

On admission to our hospital (day 15), she presented with a fever and general malaise. She did not smoke or consume alcohol or travel, and she had no remarkable medical history. Her grandfather had a history of tuberculosis three years prior, and she occasionally interacted with him. Her body temperature was 40 °C, heart rate 90 beats/min, blood pressure 109/62 mmHg, respiratory rate 18 breaths/min, and oxygen saturation 93% under normal conditions. On a physical examination, the edge of the liver could be felt 2-3 cm below the right costal margin without splenomegaly or lymphadenopathy. There were no rales on chest auscultation, and a cardiac examination revealed a regular rate and rhythm with no murmurs. Chest X-ray and CT obtained on admission revealed consolidation in the left upper lung field, ground-glass opacity in both lungs, and multiple mediastinal lymphadenopathy ([Fig. 2](#g002){ref-type="fig"}). Abdominal ultrasound showed hepatosplenomegaly with coursing echogenicity of the liver. Laboratory work-up revealed decreased levels of hemoglobin and elevated levels of AST, ALT, ALP, γ-GTP, LDH, CRP, TG, fibrinogen, FDP, D-dimer, ferritinm, sIL-2R, and ACE ([Table 1](#t001){ref-type="table"}). A peripheral blood smear showed monocytosis with hemophagocytosis. Further evaluations, including (1,3)β-D-glucan, legionella, mycoplasma, chlamydia, cytomegalovirus, Epstein-Barr virus antigen titers, and HIV ELISA, were all negative. The result of QuantiFERON-TB 3Gold (QFT-3G) was indeterminate. Several sets of blood cultures were negative, and sputum culture disclosed only yeast-like microorganisms.

![A chest X-ray and CT obtained on admission revealed consolidation in the left upper lung field, decreased ground-glass opacity in both lungs, and multiple mediastinal lymphadenopathy.](1349-7235-56-1591-g002){#g002}

###### 

Laboratory Data Obtained at Our Hospital.

  -------------- ------------------- ------- ---------------------- ------- -------
  Hematology     Coagulation study                                          
  WBC            7.54×10^3^          /μL     PT                     89      \%
  Neu            81.9                \%      APTT                   34.9    sec
  Mon            2.2                 \%      Fig                    466.0   mg/dL
  Lym            13.6                \%      FDP                    8.8     µg
  RBC            313×10^4^           /μL     D-dimer                5.7     µg/mL
  Hb             7.6                 g/dL    Serological tests              
  Plt            20.1×10^4^          /μL     IgG                    1,317   mg/dL
  ESR            40                  mm      IgA                    477.1   mg/L
  Biochemistry   IgM                 109.8   mg/dL                          
  AST            54                  U/L     KL-6                   1,100   U/mL
  ALT            108                 U/L     Antinuclear antibody   \<40    
  LDH            386                 U/L     RF                     10      U/mL
  ALP            674                 U/L     sIL-2R                 5,255   pg/mL
  γ-GTP          290                 U/L     ACE                    28.5    U/L
  CPK            8                   U/L                                    
  BUN            22                  mg/dL                                  
  Cr             0.6                 mg/dL                                  
  TP             6.9                 g/dL                                   
  Alb            3.0                 g/dL                                   
  TG             270                 mg/dL                                  
  CRP            3.88                mg/dL                                  
  Ferritin       1,582               ng/mL                                  
  -------------- ------------------- ------- ---------------------- ------- -------

On day 22, pancytopenia developed (white blood count cell count of 2,320×10^3^/μL, hemoglobin 7.3 g/dL, platelet count 8.0×10^4^/μL), and these results and clinical course suggested potential diagnoses of HPS, malignant lymphoma, sarcoidosis, hypersensitivity pneumonia, and tuberculosis. Therefore, we performed a bone marrow biopsy and TBLB again (day 23). The biopsy showed hemophagocytosis and noncaseating granulomatous inflammation without evidence of acid-fast bacilli or lymphoma. TBLB also disclosed noncaseating epithelioid granulomatous inflammation without evidence of acid-fast bacilli ([Fig. 3](#g003){ref-type="fig"}). After a bronchoscopic examination, she developed respiratory failure, and steroid pulse therapy (intravenous methylprednisolone 1,000 mg/body for three days) was started on the same day. Both acid-fast staining and tuberculosis-polymerase chain reaction (PCR) testing of the BALF showed negative results. On day 24, we learned that the BALF culture obtained at the previous hospital had grown *Mycobacterium tuberculosis*. The patient then underwent tuberculosis-PCR testing of the urine, and the result was positive. Our patient now met five of the eight criteria for HPS ([@B1]). Therefore, a diagnosis of tuberculosis associated with HPS was given.

![Bone marrow biopsy showed hemophagocytosis (A) and non-caseating granulomatous inflammation without evidence of acid-fast bacilli or lymphoma (B). TBLB also disclosed noncaseating epithelioid granulomatous inflammation without evidence of acid-fast bacilli (C) and show Langhans giant cells (arrow on B and C).](1349-7235-56-1591-g003){#g003}

Antituberculous therapy (isoniazid 5 mg/kg/day, rifampicin 10 mg/kg/day, ethambutol 15 mg/kg/day, and pyrazinamide 20 mg/kg/day) was started on day 24. She responded well to the treatment, and her fever and respiratory failure improved on day 31. In addition, her hematological abnormalities resolved, and her radiological abnormalities improved on day 38. Four weeks later, it was revealed that the sputum culture obtained on admission at our hospital had also grown *M. tuberculosis*. The patient has been in a stable condition without any recurrence during or after treatment for two years.

Discussion
==========

We herein reported a rare case of miliary tuberculosis-associated HPS complicated with respiratory failure.

HPS is a rare disorder of the immune system characterized by the benign proliferation of mature histiocytes giving rise to cytopenias. HPS is classified into primary (familial) and secondary forms. Primary HPS is an autosomal recessive disorder, usually presenting in infancy. Secondary HPS has been associated with infections, autoimmune diseases, malignancies, or drugs. Various infections activate macrophages or T cells, and the overproduction of proinflammatory cytokines by these cells is thought to be important in the monocyte/macrophage activation. Viral infection is the most frequent etiology of HPS, and to our knowledge, only 68 cases of tuberculosis-associated HPS have been reported in detail in the English literature. Furthermore, only 10 cases of tuberculosis-associated HPS in subjects under 20 years of age have been reported ([@B2]-[@B15]).

Tuberculosis-associated HPS has a high mortality rate (approximately 45%) that reaches nearly 100% without anti-tuberculous treatment ([@B2],[@B16]). This high mortality rate is mainly due to the under-recognition of this condition and delayed initiation of treatment. In our patient, the diagnosis of miliary tuberculosis was difficult because CT did not show a typical miliary nodular pattern, the acid-fast stains of the sputum and BALF were negative, and the results of QFT-3G were indeterminate. Therefore, we had to wait on the results of mycobacterial culture. The indeterminate results on the QFT-3G test in our patient were thought to be due to the influence of steroid pulse therapy performed at the previous hospital. The possibility of adult-onset immunodeficiency (patients with anti-interferon-γ-specific autoantibody) was also considered; however, our patient did not show any characteristic clinical manifestations, such as neutrophilic dermatosis, lymphatic obstruction, pain, neuropathy, hypercalcemia, erythema nodosum, or exanthematous pustulosis ([@B17]). Furthermore, in our patient, noncaseating granulomas were detected in the lung and bone marrow biopsy specimens. In the absence of caseating granulomas, it is difficult to differentiate tuberculosis from other diseases. Noncaseating granulomas are a typical pathological finding in nontuberculous mycobacterial infection, sarcoidosis, hypersensitivity pneumonitis, mycosis, and Crohn\'s disease. In tuberculosis, caseating granulomas are the typical pathological finding, although noncaseating granulomas are also found in about 45% of patients ([@B18],[@B19]).

We were unable to classify our patient with primary or secondary tuberculosis. She likely did not develop primary tuberculosis via exposure to her grandfather, because her grandfather\'s tuberculosis had been treated three years prior and did not recur after that. Furthermore, she had no striking radiologic findings, such as pulmonary parenchymal opacities with ipsilateral hilar and contiguous mediastinal lymphadenopathies, or pleural effusions. However, because primary tuberculosis shows a non-specific appearance and military tuberculosis is seen in both primary and secondary tuberculosis, the possibility of primary tuberculosis resulting from exposure to another person with tuberculosis cannot be wholly ruled out. However, we were unable to identify any potential carrier.

Regarding the possibility of secondary tuberculosis, she had no typical radiologic findings of this condition, such as patchy consolidation, poorly defined linear and nodular opacities, or cavitary lesions in the lung in the posterior segments of the upper lobes or superior segments of the lower lobes. She also had no old inflammatory parenchymal changes or lymphadenopathies. Furthermore, she was believed to be immunocompetent because laboratory tests of her immune status were normal and because no tuberculosis or other infectious diseases has developed in the two years since her anti-tuberculosis treatment.

Our patient was complicated with acute respiratory failure with diffusely distributed ground-glass attenuation of both lungs. Miliary tuberculosis accounts for around 2% of cases of acute respiratory distress syndrome (ARDS), and the mortality rate of this condition is high (ranging from 58-88%) ([@B20]-[@B23]). Our patient underwent steroid pulse therapy at the previous hospital and our hospital before the initiation of anti-tuberculosis drugs, which seemed to be temporarily effective. Treatment with corticosteroids in patients with tuberculosis remains controversial. Critchley et al. reported that corticosteroid therapy reduced the mortality rate by 17% for all forms of tuberculosis ([@B24]), and Smego et al. also reported that corticosteroid therapy can provide clinical benefits in patients with advanced pulmonary tuberculosis ([@B25]). We therefore believe that the adjunctive steroid therapy was a somewhat effective treatment in the present patient.

In addition to this case, we reviewed another 10 cases reported in the English literature of subjects under 20 years of age with tuberculosis-associated HPS ([Table 2](#t002){ref-type="table"}) ([@B4],[@B7]-[@B14]). In these cases, only two died, one of whom did not receive antituberculous therapy. Therefore, the early diagnosis and appropriate treatment is thought to be very important, especially in relatively young patients.

In conclusion, tuberculosis should be considered in the differential diagnosis for patients presenting with HPS at any age. The early diagnosis and appropriate treatment can increase the chances of survival.

###### 

Summary of Previous Reports of Tuberculosis-associated HPS Patients under 20 Years of Age.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Reference   Sex   Age        Sites where TB was isolated                              Co-morbidities   Immunotherapy          TB\         Outcome
                                                                                                                                treatment   
  ----------- ----- ---------- -------------------------------------------------------- ---------------- ---------------------- ----------- ---------
  \[6\]       F     14 days    Lungs, blood                                             N/As             Yes\                   Yes         Survive
                                                                                                         (hydrocortisone)                   

  \[7\]       F     7 weeks    Lungs                                                    N/A              No                     No          Death

  \[8\]       M     52 days    Lungs, liver, and lymphnodes                             Seborrhoeic\     Yes\                   Yes         Death
                                                                                        dermatitis       (IVIG)                             

  \[9\]       M     2 months   Bone marrow                                              No               No                     Yes         Survive

  \[10\]      F     9 years    Lungs, bone marrow, liver, spleen, and central nervous   N/A              Yes\                   Yes         Survive
                                                                                                         (prednisone)                       

  \[11\]      F     14 years   Lungs and bone marrow                                    No               Yes\                   Yes         Survive
                                                                                                         (dexamethasone/IVIG)               

  \[12\]      F     14 years   Lungs and bone marrow                                    N/A              Yes\                   Yes         Survive
                                                                                                         (epipodophyllotoxin)               

  \[13\]      M     15 years   Bone marrow, liver, spleen, and lymph node               N/A              Yes\                   Yes         Survive
                                                                                                         (IVIG)                             

  \[14\]      M     17 years   Bone marrow, and lymph nodes                             N/A              Yes\                   Yes         Survive
                                                                                                         (dexamethasone)                    

  \[25\]      F     18 years   Lungs                                                    No               Yes\                   Yes         Survive
                                                                                                         (corticosteroids)                  

  Our case    F     19 years   Lungs and bone marrow                                    No               Yes\                   Yes         Survive
                                                                                                         (prednisone)                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------

IVIG: intravenous immunoglobulin, N/A: not available, TB: tuberculosis

Modified from Shea et al. Hong Kong Med J 2012; 18: 517-525. (2)
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